August 2017

HelixBind awarded a $2.0M Phase II SBIR from the National Institutes of Health (NIH) to further development of a culture-free, sample-to-answer test for detecting and identifying microbial pathogens prevalent in neonatal sepsis.

Alon Singer
April 2017

USPTO issues HelixBind patent US 14/402,028 covering methods and compositions of matter for diagnosing sepsis

Alon Singer
August 2016

HelixBind awarded a $2.4M Direct-to-Phase II SBIR from the National Institutes of Health (NIH) to automate its sample-to-answer test for discriminating among bacterial pathogens

Alon Singer
March 2016

HelixBind published its work, completed in collaboration with Tufts Medical Center and Sloan Memorial Kettering Cancer Center demonstrating successful implementation of its novel sample-to-answer Core Pathogen Identification (C/PID) platform for identifying bloodstream infections directly from patient specimens in under 2.5 hours. For more information:
https://mbio.asm.org/content/7/2/e00345-16

 

Alon Singer
July 2015

HelixBind awarded $1.5M Phase II SBIR from the National Institutes of Health (NIH)

Alon Singer